Partner Therapeutics, Inc. (PTx)
19 Muzzey Street
About Partner Therapeutics, Inc. (PTx)
We're all in for the fight against cancer. Partner Therapeutics (PTx) is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients. We are united in our passion for improving the treatment of cancer and our desire to make a meaningful contribution to outcomes.
The patient is number one. We believe that being a cancer company begins and ends with the patient. We strive to support patient needs throughout their treatment journey to help them make the treatment choices that are right for them and their loved ones.
25 articles with Partner Therapeutics, Inc. (PTx)
9/18/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Experienced industry physician scientist to lead clinical development Co-founder, Dr. Debasish Roychowdhury, to serve as Chief Technology Officer [15-September-2020] LEXINGTON, Mass. , Sept. 15, 2020 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today its appointment of Edwin Rock , MD, PhD to serve as the c
9/14/2020It was a busy week for clinical trial updates. Here’s a look.
Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma
Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the resumption of enrollment in the National Cancer Institute (NCI) sponsored Study EA6141 1 being conducted by ECOG-ACRIN Cancer Research Gro
8/31/2020As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in COVID-19 Patients
Study builds on extensive research showing that granulocyte-macrophage colony stimulating factor (GM-CSF) is needed for effective immune function in the lungs iLeukPulm Phase 2 Clinical TrIal Supported by $35 Million Contract from U.S. Department of Defense [25-August-2020] LEXINGTON, Mass. , Aug. 25, 2020 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a
8/10/2020It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
Partner Therapeutics Announces $35 Million Contract with U.S. Department of Defense for Advanced Development and Emergency Use of Leukine® (rhuGM-CSF) for COVID-19 Acute Hypoxemic Respiratory Failure (AHRF)
Funding will support two randomized, multi-center clinical trials in COVID-19 patients, expansion of manufacturing capacity and potential Emergency Use Authorization filing
6/15/2020It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Partner Therapeutics Announces Initiation of Clinical Trial Evaluating Leukine® in T Cell Replete HLA-mismatched Haploidentical Stem Cell Transplant
Partner Therapeutics, a commercial biotechnology company, announces the enrollment of the first patient dosed in a Phase II investigator-initiated study evaluating the efficacy and safety of Leukine ® (sargramostim, rhu-GM-CSF) in T cell replete HLA-mismatched haploidentical stem cell transplant recipients who are receiving post-
Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine® in Respiratory Illness in Patients with COVID-19 at Singapore General Hospital
Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the initiation of an investigator-initiated randomized, double-blind, placebo-controlled clinical trial of Leukine (sargramostim, rhu-GM-CSF) in patients with acute respiratory failure associated with COVID-19, conducted at Singapore General Hospital (NCT04400929).
Tanner Pharma Group Announces LEUKINE EMERGENCY ACCESS PROGRAM (LEAP) to Provide Increased International Access to LEUKINE® (sargramostim)
Tanner Pharma Group today announced they are expanding their program by which the company provides access to LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA in 1991 and now manufactured by Partner Therapeutics, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infec
Partner Therapeutics Announces Initiation of Clinical Trial to Evaluate Leukine® in Patients with COVID-19 Associated Respiratory Illness
Partner Therapeutics, Inc. (PTx) announced that Leukine® (sargramostim, rhu-GM-CSF) is being assessed in the SARPAC trial (sargramostim in patients with acute hypoxic respiratory failure due to COVID-19 – EudraCT #2020-001254-22) at University Hospital Ghent to treat patients with respiratory illness associated with COVID-19.
Former Aeolus CEO will lead business development and government relations
Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine® (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF), for the potential treatment of Stage IIb-IV melanoma.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Partner Therapeutics Receives FDA Orphan Drug Designation for Leukine® for the Treatment of Pulmonary Alveolar Proteinosis
Partner Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Leukine®.
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome
Improves survival when initiated 48 hours after radiation exposure